132 related articles for article (PubMed ID: 27189164)
21. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Biliran H; Wang Y; Banerjee S; Xu H; Heng H; Thakur A; Bollig A; Sarkar FH; Liao JD
Clin Cancer Res; 2005 Aug; 11(16):6075-86. PubMed ID: 16115953
[TBL] [Abstract][Full Text] [Related]
22. β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.
Kallifatidis G; Smith DK; Morera DS; Gao J; Hennig MJ; Hoy JJ; Pearce RF; Dabke IR; Li J; Merseburger AS; Kuczyk MA; Lokeshwar VB; Lokeshwar BL
Mol Cancer Ther; 2019 Apr; 18(4):801-811. PubMed ID: 30787175
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells.
Zhang S; Chang YY; Gong YW; Gao YJ; Guo Q; Wang YH; Zhao YL; Wang ZP
J Cell Biochem; 2019 Apr; 120(4):6347-6360. PubMed ID: 30304549
[TBL] [Abstract][Full Text] [Related]
24. Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
Shi ZD; Hao L; Han XX; Wu ZX; Pang K; Dong Y; Qin JX; Wang GY; Zhang XM; Xia T; Liang Q; Zhao Y; Li R; Zhang SQ; Zhang JH; Chen JG; Wang GC; Chen ZS; Han CH
Mol Cancer; 2022 Feb; 21(1):37. PubMed ID: 35130920
[TBL] [Abstract][Full Text] [Related]
25. Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
Yang Y; Zhang G; Li J; Gong R; Wang Y; Qin Y; Ping Q; Hu L
Pathol Res Pract; 2021 Dec; 228():153676. PubMed ID: 34753061
[TBL] [Abstract][Full Text] [Related]
26. Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Lu J; Zhang Y; Wu C; Chu C; Liu Z; Cao Y
Jpn J Clin Oncol; 2021 Mar; 51(3):424-433. PubMed ID: 33319245
[TBL] [Abstract][Full Text] [Related]
27. Expression landscape of cancer-FOXP3 and its prognostic value in pancreatic adenocarcinoma.
Gong R; Wang J; Xing Y; Wang J; Chen X; Lei K; Yu Q; Zhao C; Li S; Zhang Y; Wang H; Ren H
Cancer Lett; 2024 May; 590():216838. PubMed ID: 38561039
[TBL] [Abstract][Full Text] [Related]
28. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Wang S; Zhang H; Scharadin TM; Zimmermann M; Hu B; Pan AW; Vinall R; Lin TY; Cimino G; Chain P; Vuyisich M; Gleasner C; Mcmurry K; Malfatti M; Turteltaub K; de Vere White R; Pan CX; Henderson PT
PLoS One; 2016; 11(1):e0146256. PubMed ID: 26799320
[TBL] [Abstract][Full Text] [Related]
29. Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
An Q; Zhou L; Xu N
Biomed Pharmacother; 2018 Jul; 103():415-420. PubMed ID: 29674277
[TBL] [Abstract][Full Text] [Related]
30. MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
da Silva GN; de Camargo EA; Sávio AL; Salvadori DM
Mol Biol Rep; 2014 Jul; 41(7):4613-21. PubMed ID: 24652204
[TBL] [Abstract][Full Text] [Related]
31. Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
Li B; Xie D; Zhang H
Cancer Chemother Pharmacol; 2019 Jul; 84(1):187-194. PubMed ID: 31115606
[TBL] [Abstract][Full Text] [Related]
32. ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.
Chen MH; Weng JJ; Cheng CT; Wu RC; Huang SC; Wu CE; Chung YH; Liu CY; Chang MH; Chen MH; Chiang KC; Yeh TS; Su Y; Yeh CN
Clin Cancer Res; 2016 Aug; 22(16):4225-35. PubMed ID: 27076629
[TBL] [Abstract][Full Text] [Related]
33. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
[TBL] [Abstract][Full Text] [Related]
34. Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Rutz J; Maxeiner S; Juengel E; Chun FK; Tsaur I; Blaheta RA
Nutrients; 2022 Jan; 14(2):. PubMed ID: 35057550
[TBL] [Abstract][Full Text] [Related]
35.
Wei W; Sun J; Zhang H; Xiao X; Huang C; Wang L; Zhong H; Jiang Y; Zhang X; Jiang G
Cancer Res; 2021 Dec; 81(24):6142-6156. PubMed ID: 34702726
[TBL] [Abstract][Full Text] [Related]
36. A Novel Long Non-Coding RNA KMU15 Promotes Growth and Chemoresistance of Bladder Cancer.
Huang Y; Luan T; Bao X; Fu S; Li N; Li H; Wang H; Li C; Wang J
Clin Lab; 2019 Dec; 65(12):. PubMed ID: 31850704
[TBL] [Abstract][Full Text] [Related]
37. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
38. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia-elevated circELP3 contributes to bladder cancer progression and cisplatin resistance.
Su Y; Yang W; Jiang N; Shi J; Chen L; Zhong G; Bi J; Dong W; Wang Q; Wang C; Lin T
Int J Biol Sci; 2019; 15(2):441-452. PubMed ID: 30745833
[TBL] [Abstract][Full Text] [Related]
40. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
